Current Liabilities
Accounts Payable
Vertex Pharmaceuticals Accounts Payable increased by 6.0% to $489.3M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.0%, from $445M to $489.3M. Over 5 years (FY 2020 to FY 2025), Accounts Payable shows an upward trend with a 24.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase can signal improved cash management or delayed payments, while a decrease may indicate faster settlement of obligations.
Detailed definition
This represents the short-term obligations owed to suppliers and vendors for goods or services received on credit. It se...
Peer comparison
Standard across all industries; biotech firms typically maintain moderate levels relative to their operational scale.
Metric ID:
accounts_payableHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $127.53M | $127.86M | $195M | $173.6M | $198M | $126.9M | $303.9M | $323.2M | $363M | $375.9M | $364.9M | $351.4M | $327.9M | $395.8M | $413M | $445M | $442.3M | $420.3M | $461.7M | $489.3M |
| QoQ Change | — | +0.3% | +52.5% | -11.0% | +14.1% | -35.9% | +139.5% | +6.4% | +12.3% | +3.6% | -2.9% | -3.7% | -6.7% | +20.7% | +4.3% | +7.7% | -0.6% | -5.0% | +9.9% | +6.0% |
| YoY Change | — | — | — | — | +55.3% | -0.8% | +55.8% | +86.2% | +83.3% | +196.2% | +20.1% | +8.7% | -9.7% | +5.3% | +13.2% | +26.6% | +34.9% | +6.2% | +11.8% | +10.0% |
Range$126.9M – $489.3M
CAGR+32.7%
Avg YoY Growth+37.7%
Median YoY Growth+16.6%
Current Streak2 quarters growth
Accounts Payable at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's accounts payable?
- Vertex Pharmaceuticals (VRTX) reported accounts payable of $489.3M in Q1 2026.
- How has Vertex Pharmaceuticals's accounts payable changed year-over-year?
- Vertex Pharmaceuticals's accounts payable increased by 10.0% year-over-year, from $445M to $489.3M.
- What is the long-term trend for Vertex Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's accounts payable has grown at a 24.4% compound annual growth rate (CAGR), from $155.1M to $461.7M.
- What does accounts payable mean?
- The amount of money the company owes to its suppliers for goods and services already received.